<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
TVTX
Travere Therapeutics
$
()


  • Travere Therapeutics price target raised by $3 at Canaccord, here's why

    5/7/2024 - 07:37am
  • Travere Therapeutics reports Q1 EPS (1.51) , consensus (99c)

    5/6/2024 - 16:08pm
  • Travere Therapeutics price target raised by $2 at H.C. Wainwright, here's why

    4/24/2024 - 12:27pm
  • Travere Therapeutics, CSL Vifor announce EC approves FILSPARI

    4/24/2024 - 07:10am
  • Travere Therapeutics, CSL Vifor announce EC approval for Filspari

    4/24/2024 - 05:21am
  • Travere downgraded to Neutral at Guggenheim on smaller role in IgAN space

    3/27/2024 - 09:24am
  • Guggenheim gets more bearish on Travere Therapeutics, downgrades shares

    3/27/2024 - 06:43am
  • Travere Therapeutics submits sNDA for FILSPARI for IgAN

    3/11/2024 - 07:42am
  • Travere Therapeutics price target lowered by $3 at H.C. Wainwright, here's why

    2/23/2024 - 10:23am
  • Travere , CSL Vifor announce Sparsentan received positive CHMP opinion

    2/23/2024 - 07:09am
  • Travere Therapeutics, CSL Vifor get CHMP recommendation for sparsentan approval

    2/23/2024 - 05:14am
  • Travere Therapeutics price target raised by $4 at Citi, here's why

    2/16/2024 - 17:23pm
  • Travere Therapeutics reports Q4 EPS (94c), consensus ($1.22)

    2/15/2024 - 16:12pm
  • Travere in $120M licensing deal with Renalys to develop sparsentan in Asia

    1/25/2024 - 16:25pm
  • Travere Therapeutics price target raised by $3 at TD Cowen, here's why

    1/25/2024 - 07:37am
dynamic_feed Breaking News